Top Page
Inoviq Ltd
(Sydney:IIQ)
Inoviq Ltd (IIQ) vs. iShares MSCI Australia ETF (EWA)
Inoviq Ltd Business Overview & Revenue Model
Inoviq Ltd Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.22M | 1.82M | 535.12K | 398.19K | 276.75K | 1.27M |
| Gross Profit | -583.05K | -1.56M | 454.11K | -1.04M | -1.88M | -2.21M |
| EBITDA | -7.87M | -6.16M | -6.34M | -9.32M | -19.39M | -6.05M |
| Net Income | -7.24M | -6.93M | -6.55M | -8.97M | -18.20M | -11.15M |
Balance Sheet | ||||||
| Total Assets | 24.52M | 18.46M | 21.71M | 21.51M | 30.78M | 33.52M |
| Cash, Cash Equivalents and Short-Term Investments | 13.80M | 6.52M | 9.23M | 7.81M | 15.39M | 5.00M |
| Total Debt | 270.31K | 376.19K | 776.54K | 730.71K | 998.69K | 1.26M |
| Total Liabilities | 2.26M | 1.74M | 1.72M | 1.89M | 2.49M | 4.46M |
| Stockholders Equity | 22.26M | 16.71M | 19.99M | 19.62M | 28.29M | 29.06M |
Cash Flow | ||||||
| Free Cash Flow | -5.08M | -4.77M | -4.50M | -7.32M | -6.47M | -6.05M |
| Operating Cash Flow | -4.99M | -4.66M | -4.32M | -7.02M | -6.06M | -5.26M |
| Investing Cash Flow | -88.12K | -104.00K | -174.34K | -292.27K | -411.90K | 2.64M |
| Financing Cash Flow | 9.41M | 2.05M | 5.91M | -267.98K | 16.87M | 286.48K |
Inoviq Ltd Technical Analysis
Inoviq Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$243.30M | -7.39 | -111.23% | ― | 12.96% | 40.81% | |
45 Neutral | AU$42.40M | -2.45 | -164.22% | ― | ― | 23.85% | |
43 Neutral | AU$76.09M | -4.75 | -501.54% | ― | ― | 56.42% | |
41 Neutral | AU$18.85M | -2.23 | -36.16% | ― | 62.81% | 16.37% | |
38 Underperform | AU$45.75M | -3.01 | -37.14% | ― | 2.33% | 12.50% |
Inoviq Ltd Corporate Events
Inoviq Limited has disclosed a change in director Peter Gunzburg’s indirect shareholding following an on-market purchase. Gunzburg acquired 50,000 ordinary shares at $0.33 per share on 2 March 2026 through associated entities, lifting his total indirect interest to 3,486,714 ordinary fully paid shares and 315,000 listed options.
The transaction, reported to the ASX under director interest rules, signals a modest increase in insider ownership but does not alter the company’s capital structure. Stakeholders may view the purchase as a show of confidence from a board member, although the notice does not provide commentary on company performance or strategic developments.
The most recent analyst rating on (AU:IIQ) stock is a Hold with a A$0.37 price target. To see the full list of analyst forecasts on Inoviq Ltd stock, see the AU:IIQ Stock Forecast page.
Inoviq has disclosed a change in the indirect interests of director Peter Gunzburg, who has increased his stake in the company through associated entities. On 19 February 2026, Gunzburg acquired 100,000 ordinary shares on-market at $0.33 each, lifting his total holding to 3,436,714 ordinary shares and 315,000 listed options, signalling continued insider confidence in the stock.
The additional shares are spread across multiple private vehicles, including Supergun Pty Ltd and Rivista Pty Ltd, which already held substantial positions. While the transaction is relatively modest in size, it marginally strengthens director alignment with shareholders and provides the market with updated visibility on insider ownership levels in Inoviq.
The most recent analyst rating on (AU:IIQ) stock is a Sell with a A$0.33 price target. To see the full list of analyst forecasts on Inoviq Ltd stock, see the AU:IIQ Stock Forecast page.
In its December quarterly update, Inoviq reported continued commercial uptake of its EXO-NET exosome capture technology, with 76 customers by year-end and growing demand from pharma, biotech and clinical users despite broader funding uncertainty in the life sciences tools sector. The company advanced its EXO-OC exosome-based ovarian cancer screening test toward larger clinical studies after earlier data showed 100% sensitivity for early-stage disease and more than 99.6% specificity, and it is targeting Laboratory Developed Test readiness by end-2026 while exploring US laboratory partnerships. Inoviq also announced strong in vivo proof-of-concept results for its EGFR-targeted CAR-NK exosome therapy in a triple-negative breast cancer mouse model, demonstrating superior tumour inhibition, favourable safety and precise tumour targeting, and is accelerating this program into preclinical and manufacturing development with a view to first-in-human studies in 2028. Complementing these programs, the company is further developing its neuCA15-3 blood test for breast cancer monitoring into a high-throughput assay ahead of additional clinical validation and potential partnering, while shoring up its balance sheet with a A$10.2 million capital raise and ending the quarter with $13.8 million in cash, alongside leadership changes including a new chairman and chief scientific officer to support its next growth phase.
The most recent analyst rating on (AU:IIQ) stock is a Hold with a A$0.37 price target. To see the full list of analyst forecasts on Inoviq Ltd stock, see the AU:IIQ Stock Forecast page.
Inoviq Ltd has notified the market of the issue of 700,000 unquoted options under its employee incentive scheme, recorded as Appendix 3G with the ASX. The options, which have various expiry dates and exercise prices and are not intended to be quoted on the exchange, form part of Inoviq’s remuneration and retention strategy for staff, underscoring the company’s use of equity-based incentives to align employees with long-term shareholder value and operational goals.
The most recent analyst rating on (AU:IIQ) stock is a Hold with a A$0.37 price target. To see the full list of analyst forecasts on Inoviq Ltd stock, see the AU:IIQ Stock Forecast page.
INOVIQ has appointed internationally recognised exosome and cell therapy specialist Dr Rebecca Lim as Chief Scientific Officer, effective 12 January 2026, to lead its research and development strategy across preclinical, clinical and regulatory programs in exosome capture tools, diagnostics and therapeutics. Lim’s more than 20 years’ experience in translational research, advanced therapy development and regulatory navigation in Australia and the US is expected to accelerate INOVIQ’s CAR-exosome therapeutic pipeline toward first-in-human studies and strengthen the company’s global leadership ambitions in exosome technologies, while founder Professor Greg Rice transitions to a part-time role as Founding Scientist and Advisor to ensure continuity of scientific oversight and diagnostics leadership during the next phase of growth.
The most recent analyst rating on (AU:IIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Inoviq Ltd stock, see the AU:IIQ Stock Forecast page.
INOVIQ has reported positive in vivo proof-of-concept data for its EGFR-targeted CAR-NK exosome therapy in a triple-negative breast cancer mouse model, with its CAR-NK-EVs delivering a 61.5% tumour reduction over 28 days, 100% survival in treated mice, and a favourable safety profile compared with controls. The study also showed improved precision targeting with reduced non-specific liver accumulation, validating the company’s EXO-ACE manufacturing platform and underpinning a newly filed provisional patent on CAR-targeting and exosome purification, which strengthens INOVIQ’s intellectual property position and supports the advancement of its off-the-shelf, cell-free immunotherapy platform for hard-to-treat solid tumours.
The most recent analyst rating on (AU:IIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Inoviq Ltd stock, see the AU:IIQ Stock Forecast page.
Inoviq Ltd has notified the ASX that 2.3 million options (security code IIQAE), which were due to expire on various dates and at various exercise prices, have lapsed because the conditions required for conversion into securities were not, or could no longer be, satisfied. The cessation of these options slightly reduces the company’s pool of potential equity on issue, which may marginally affect future dilution expectations for existing shareholders but has no immediate impact on current issued share capital.
The most recent analyst rating on (AU:IIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Inoviq Ltd stock, see the AU:IIQ Stock Forecast page.
INOVIQ Limited has announced that director David Williams ceased to be a director on 18 December 2025, lodging a final director’s interest notice with the ASX in accordance with listing requirements. The notice details Williams’ remaining interests in INOVIQ securities, including substantial holdings of ordinary fully paid shares held via several private entities, employee options and listed options, clarifying his equity position for investors and ensuring continued transparency around major shareholder and governance changes following his departure from the board.
The most recent analyst rating on (AU:IIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Inoviq Ltd stock, see the AU:IIQ Stock Forecast page.
INOVIQ Ltd has announced a leadership transition with David Williams stepping down as Chairman, effective December 18, 2025, and Peter Gunzburg taking over the role. Gunzburg emphasized the company’s readiness to advance its well-funded product development strategy, marking a significant phase in achieving milestones to benefit patients, partners, and shareholders.
The most recent analyst rating on (AU:IIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Inoviq Ltd stock, see the AU:IIQ Stock Forecast page.